Shrestha Chandani, Yoo Eun Hee, Deshar Barsha, Hwang Min, Kang Shinwon, Bin Bum-Ho, Lee Ji Hyun, Kim Jiyoon
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591; Department of Medical Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.
Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
BMB Rep. 2025 Aug;58(8):357-363.
Rosacea is a chronic inflammatory skin disorder characterized by facial erythema, papules, pustules, and telangiectasia, affecting approximately 5.5% of the global population. Current treatments, primarily topical and oral antibiotics and anti-inflammatories, often show limited efficacy and may cause undesirable side effects, prompting the need for alternative therapies. Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has shown promise as a therapeutic agent for rosacea due to its anti-inflammatory, antioxidant, and anti-apoptotic properties. CBD interacts with the endocannabinoid system, which plays a crucial role in cutaneous homeostasis. This study evaluated the efficacy of CBD, both alone and in combination with metronidazole (MET), in reducing inflammation and modulating immune responses in a rosacea-like mouse model. Our results demonstrated that both CBD and MET significantly inhibited redness, epidermal thickness, and mast cell infiltration, with their combination being more effective. Mechanistic analyses revealed that the therapeutic effect of CBD is associated with the suppression of key inflammatory regulators in the MAPK signaling pathway, particularly the ERK, JNK, and p38 pathways. CBD treatment also led to a significant reduction in pro- inflammatory cytokines and chemokines, indicating immune modulation. These findings suggest that CBD, especially in combination with MET, may represent a novel therapeutic option for rosacea and offer a scientific basis for its clinical application in managing inflammatory skin conditions. [BMB Reports 2025; 58(8): 357-363].
酒渣鼻是一种慢性炎症性皮肤病，其特征为面部红斑、丘疹、脓疱和毛细血管扩张，影响全球约5.5%的人口。目前的治疗方法主要是局部和口服抗生素以及抗炎药，往往疗效有限，还可能引起不良副作用，因此需要替代疗法。大麻二酚（CBD）是大麻的一种非精神活性成分，由于其抗炎、抗氧化和抗凋亡特性，已显示出作为酒渣鼻治疗剂的潜力。CBD与内源性大麻素系统相互作用，该系统在皮肤稳态中起关键作用。本研究评估了CBD单独使用以及与甲硝唑（MET）联合使用在减少酒渣鼻样小鼠模型中的炎症和调节免疫反应方面的疗效。我们的结果表明，CBD和MET均能显著抑制发红、表皮厚度和肥大细胞浸润，两者联合使用效果更佳。机制分析显示，CBD的治疗效果与抑制丝裂原活化蛋白激酶（MAPK）信号通路中的关键炎症调节因子有关，特别是细胞外信号调节激酶（ERK）、c-Jun氨基末端激酶（JNK）和p38通路。CBD治疗还导致促炎细胞因子和趋化因子显著减少，表明其具有免疫调节作用。这些发现表明，CBD，尤其是与MET联合使用时，可能代表酒渣鼻的一种新型治疗选择，并为其在管理炎症性皮肤病中的临床应用提供科学依据。[《BMB报告》2025年；58(8): 357 - 363]
